Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
6.8.2021 12:13:00 EEST | Business Wire | Press release
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) used to treat various types of macular-degenerative diseases such as neovascular (wet) age-related macular degeneration, diabetic retinopathy, macular edemas and myopic choroidal neovascularization. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.
Subject to FDA's approval of this BLA, the product will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Said submission represents the most recent milestone for Bioeq's ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA and UK MHRA already in July this year.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented:
“The submission of a BLA to the FDA is a major milestone for any therapeutic and brings hope to patients across the US. This announcement carries a tangible promise of treatment choice and improved access to those who suffer from debilitating vision loss, including age-related macular degeneration. This is another representation of our commitment to providing safe and effective medicines to patients.”
1) Lucentis ® is a registered trademark of Genentech Inc.
About Ranibizumab biosimilar
The Ranibizumab biosimilar, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis®.
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005187/en/
Contact information
Joseph Reeds
Head of Marketing, Polpharma Biologics
Joseph.reeds@polpharmabiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Radisys Launches V.AI Ecosystem to Accelerate Telecom AI Service Innovation10.9.2026 15:00:00 EEST | Press release
Radisys® Corporation, a global leader in open telecom solutions, today announced the launch of its V.AI ecosystem, bringing together applications, development tools and leading voice and speech AI technologies to help telecom operators create, deploy and monetize AI-powered communication services for consumers and business subscribers. The V.AI ecosystem, which has evolved since the launch of the Radisys Engage Digital Platform (EDP) at MWC Barcelona in 2022, draws on two decades of Radisys leadership in real-time media processing and a global footprint across live operator networks. Seamlessly integrated with EDP, the ecosystem gives operators multiple paths to market. Operators can deploy turnkey applications, customize services for specific markets and customer segments, or create new device-independent, network-delivered experiences through V.AI Studio, Radisys’ development environment for voice and video AI services. Charter members of the V.AI ecosystem, ElevenLabs, Hiya, ReadSpe
BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology10.9.2026 15:00:00 EEST | Press release
BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910717829/en/ BioLife offers a new solution for oral GLP-1 delivery The announcement comes as demand for GLP-1 medicines continues to accelerate. GLP-1 therapies generated approximately $132 billion in global sales in 2025, while obesity medicines now represent an estimated $42 billion market.1 As more patients seek alternatives to injections, demand for alternative oral treatments continues to grow. First generation oral GLP-1 medicines have demonstrated the value of oral administration while also underscoring on the fundamental challenges in peptide drug development: protecting large peptide molecule
Netskrt to Showcase Media Over QUIC Work with Oracle at IBC 202610.9.2026 15:00:00 EEST | Press release
Netskrt, an independent content delivery network built for high-concurrency streaming events, today announced that it will showcase its work to advance Media Over QUIC (MOQ) at IBC 2026, taking place Sept. 11-14 at RAI Amsterdam. As part of the event, Netskrt will demonstrate with Oracle how independently operated CDN infrastructure can participate in a coordinated MOQ delivery path designed to bring live media closer to viewers. MOQ is an emerging IETF effort designed to support low-latency media delivery at scale, with live streaming among its primary use cases. Its relay-based architecture enables media to move through distributed infrastructure closer to audiences, creating new possibilities for reducing latency while efficiently serving highly concurrent live events. At IBC, Netskrt and Oracle will put that model into practice. An Oracle Video Edge (OVE) containerized relay running within Netskrt infrastructure will coordinate with Oracle’s relay network as part of an end-to-end M
Bending Spoons enters into a definitive agreement to acquire Miro for $1.355 billion10.9.2026 15:00:00 EEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has entered into a definitive agreement to acquire Miro at an enterprise value of $1.355 billion. Together with Miro’s net cash, this implies an equity value of approximately $1.79 billion. In connection with the all-cash transaction, certain Miro shareholders have agreed to invest $295 million of their proceeds into newly issued Bending Spoons equity. The acquisition, including the investment, is subject to customary closing conditions and approvals, including regulatory approvals. “It's a privilege, and no small responsibility, to welcome a product that over 250,000 organizations have integrated into their workflows,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro has grown to around $600 million in annual recurring revenue, nearly 90% from business and enterprise customers. After closing, we plan to invest substantially in the fundamentals that its customers value: performance, reliability, and functionality that supports critical col
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses10.9.2026 14:45:00 EEST | Press release
Johnson & Johnson (NYSE: JNJ) today announced that it has received CE Marking for ACUVUE OASYS MAX 2-Week,*** a new reusable contact lens featuring proprietary MAX technologies designed to deliver superior comfort and visual clarity, even at day 14.*†i¥1 The lens will be rolled out in select European countries later this year with wider market rollout in 2027. Globally, 140 million people wear contact lenses, with one in two choosing a reusable lens,2 and comfort remains their leading priority.3 With the continued rise in everyday use of digital devices and exposure to blue-violet light, more demands are being placed on patients’ eyes, often leading to reduced visual clarity and symptoms of dryness.4,5,6,7 ACUVUE OASYS MAX 2-Week brings Johnson & Johnson’s advanced MAX contact lens technologies to reusable contact lens wearers, helping address their evolving vision, comfort, and digital lifestyle needs. “People who choose reusable contact lenses should not have to compromise on comfort
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom